Analysts at Maxim Group began coverage on shares of Immune Pharmaceuticals (NASDAQ:IMNP) in a report released on Friday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $3.00 price target on the biopharmaceutical company’s stock. Maxim Group’s price objective would indicate a potential upside of 435.71% from the stock’s current price.
The analysts wrote, “Bertilimumab is a monoclonal antibody (mAb) targeting eotaxin-1, a chemokine implicated in multiple inflammatory diseases including bullous pemphigoid (BP) and ulcerative colitis (UC), with potential expansion to atopic dermatitis (AD) and asthma.””
Shares of Immune Pharmaceuticals (IMNP) traded down $0.01 during trading on Friday, hitting $0.56. The company had a trading volume of 783,044 shares, compared to its average volume of 622,225. The company has a debt-to-equity ratio of 3.04, a current ratio of 0.03 and a quick ratio of 0.03. Immune Pharmaceuticals has a 1 year low of $0.50 and a 1 year high of $5.02. The firm has a market cap of $10.06, a P/E ratio of -0.19 and a beta of 2.59.
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.
Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.